4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Published online 27 August 2009
Haematologica, Vol 95, Issue 2, 260-269 doi:10.3324/haematol.2009.012088
Copyright © 2010 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Todoerti et al. Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Todoerti, K.
Right arrow Articles by Golay, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Todoerti, K.
Right arrow Articles by Golay, J.

Multiple Myeloma

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b

Katia Todoerti2, Valentina Barbui1, Olga Pedrini1, Marta Lionetti2, Gianluca Fossati3, Paolo Mascagni3, Alessandro Rambaldi1, Antonino Neri2, Martino Introna1, Luigia Lombardi2, Josée Golay1

1 USC Hematology, Ospedali Riuniti di Bergamo, Bergamo
2 Department of Medical Sciences, University of Milan, Fondazione IRCCS Policlinico, Milano
3 Italfarmaco SpA, Cinisello Balsamo, Italy

Correspondence: Josée Golay, Laboratorio di Terapia Cellulare, USC Ematologia, c/o Presidio Matteo Rota, Via Garibaldi 11-13, 24128, Bergamo, Italy. E-mail: jgolay{at}ospedaliriuniti.bergamo.it

Background: The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease.

Design and Methods: In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The modulation of several genes and their biological consequence were verified in a panel of multiple myeloma cell lines and cells freshly isolated from patients by using polymerase chain reaction analysis and western blotting.

Results: Out of 38,500 human genes, we identified 140 and 574 up-regulated genes and 102 and 556 down-modulated genes at 2 and 6 h, respectively, with a significant presence of genes related to transcription regulation at 2 h and to cell cycling and apoptosis at 6 h. Several of the identified genes are particularly relevant to the biology of multiple myeloma and it was confirmed that ITF2357 also modulated their encoded proteins in different multiple myeloma cell lines. In particular, ITF2357 down-modulated the interleukin-6 receptor {alpha} (CD126) transcript and protein in both cell lines and freshly isolated patients’ cells, whereas it did not significantly modify interleukin-6 receptor β (CD130) expression. The decrease in CD126 expression was accompanied by decreased signaling by interleukin-6 receptor, as measured by STAT3 phosphorylation in the presence and absence of inter-leukin-6. Finally, the drug significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma.

Conclusions: ITF2357 inhibits several signaling pathways involved in myeloma cell growth and survival.

Key words: pleiotropic anti-myeloma, ITF2357, interleukin-6 receptor, miR-19a, miR-19b.